mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation
Frontiers in Pharmacology · 07.07.2026 · 17
DOI: 10.3389/fphar.2026.1852041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.07.2026. Verfasst von Dianzhe Tian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medi…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer remains a major global health challenge, and traditional treatments often involve significant toxicity and limited benefits for patients with advanced-stage disease. mRNA vaccines have recently emerged as a promising approach in cancer immunotherapy due to their flexibility in design, rapid production, and suitability for personalized treatment. This review summarizes the molecular basis, main classifications, and mechanisms of action of mRNA vaccines for cancer therapy and systematically discusses progress in strategies for delivering tumor-specific antigens, tumor-associated antigens, and immunomodulatory factors. Special attention is given to advances in delivery technologies, especially lipid nanoparticle (LNP) systems, and their potential applications across various cancers. We suggest that the effectiveness of mRNA cancer vaccines depends not only on selecting the right antigens but also on delivery methods that modulate the immune response and reshape the tumor microenvironment. Melanoma is a prime candidate for prioritizing the research and development of mRNA cancer vaccines, given the current clinical landscape. Furthermore, major challenges that continue to limit progress include insufficient stability, suboptimal delivery efficiency, uncontrolled immunogenicity, and the difficulty of overcoming tumor heterogeneity. This review aims to serve as a useful reference for further development and clinical translation of mRNA cancer vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Eight-Year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Pharmacology, College of Pharmaceutical Sciences of Capital Medical University, Beijing, China.
- Key Laboratory of Ocular Fundus Disease, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China.
- Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of the Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Beijing, Chin…
Zitieren
APA
Tian, D., Li, X., Yang, Z., Zhao, X., Hu, Z., Zhao, H., Du, S., Liu, S., Zhang, L., Xu, Y., & Lu, X. (2026). mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1852041
Vancouver
Tian D, Li X, Yang Z, Zhao X, Hu Z, Zhao H, et al. mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1852041
BibTeX
@article{Tian2026,
author = {Tian, Dianzhe and Li, Xinshi and Yang, Zuyi and Zhao, Xinyu and Hu, Zixuan and Zhao, Haitao and Du, Shunda and Liu, Shengzhi and Zhang, Lei and Xu, Yiyao and Lu, Xin},
title = {mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1852041}
}
EUVIMED